---
title: Recommended Chronic Therapy by HF Stage
---

# Recommended Chronic Therapy by HF Stage

(JACC 2021;77:772)

- Utility of BNP-guided Rx (inPt and outPt) remains debated (Eur Heart J 2014;35:16)
- Implantable PA pressure sensor in sx Pts: ~19-37% ↓ risk of hosp (Lancet 2016;387:453 & 2021;398:991)

## Stage (not NYHA Class) Therapy

- A

  - at ↣ risk for HF (eg, HTN); but asx & w/o struct. dis.
  - Rx HTN, lipids, DM;
    - stop smoking, EtOH;
    - ↑ exercise
  - _ACEI/ARB_ if HTN/DM/CAD/PAD

- B

  - ⊕ Struct. heart dis.
  - (eg, CMP, LVH), but asx
  - As per stage A + ACEI/ARB + _βB if MI/CAD_ or ↓ EF. ? ICD.

- C

  - ⊕ Struct. heart dis.
  - ⊕ Any h/o Sx of HF
  - As per stage A + diuretics, ↓ Na.
  - If ↓ EF:
    - ARNI, ACEI or ARB;
    - βB;
    - aldo antag;
    - SGLT2i;
    - ICD;
    - ? CRT;
    - ± nitrate/hydral;
    - ± dig.
  - If preserved EF:
    - ? ARNI;
    - ? aldo antag: Eplerenone (Inspra) Spirinolactone (Aldactone)
    - SGLT2i

- D

  - Refractory HF requiring specialized interventions
  - All measures for stages A-C. Consider IV inotropes, VAD, transplant, end-of-life care (4-y mortality >50%)
